Namonyo Samuel, Carvalho Gilda, Guo Jianhua, Weynberg Karen D
Australian Centre for Water and Environmental Biotechnology (ACWEB, formerly AWMC), The University of Queensland, St. Lucia, QLD 4072, Australia.
Queensland Alliance for Environmental Health Services, The University of Queensland, Woolloongabba, QLD 4102, Australia.
Microorganisms. 2022 Jan 19;10(2):210. doi: 10.3390/microorganisms10020210.
Multi-drug resistant (MDR) clinical strains of are the most prevalent bacteria in the lungs of patients with cystic fibrosis (CF) and burn wounds and among the most common in immunocompromised hospital patients in Australia. There are currently no promising antibiotics in the pipeline being developed against these strains. Phage therapy, which uses viruses known as bacteriophages to infect and kill pathogenic bacteria, could be a possible alternative treatment. To this end, we isolated and characterised four novel phages against Australian clinical strains of isolated from patients with cystic fibrosis, from infected blood and joint aspirate in Southeast Queensland, Australia. Activated sludge was enriched for phages using the clinical strains, and four bacteriophages were isolated. The phages were able to cause lysis in a further three identified clinical isolates. Morphology showed that they were all tailed phages (of the order Caudovirales), two belonging to the family Myoviridae and the others assigned to the Podoviridae and Siphoviridae. Their genomes were sequenced to reveal a doubled stranded DNA topology with genome sizes ranging from 42 kb to 65 kb. In isolating and characterising these novel phages, we directed our efforts toward the development and use of these phages as candidates for phage therapy as an alternative strategy for the management or elimination of these pathogenic strains. Here we describe novel phage candidates for potential therapeutic treatment of MDR Australian clinical isolates of .
多重耐药（MDR）临床菌株是囊性纤维化（CF）患者肺部、烧伤创面中最常见的细菌，在澳大利亚免疫功能低下的住院患者中也最为常见。目前尚无针对这些菌株的有前景的抗生素正在研发中。噬菌体疗法利用被称为噬菌体的病毒来感染和杀死致病细菌，可能是一种替代治疗方法。为此，我们从澳大利亚昆士兰州东南部囊性纤维化患者、感染血液和关节穿刺液中分离并鉴定了四种针对澳大利亚临床菌株的新型噬菌体。利用临床菌株对活性污泥进行噬菌体富集，分离出四种噬菌体。这些噬菌体能够在另外三种已鉴定的临床分离株中引起裂解。形态学显示它们都是有尾噬菌体（属于长尾噬菌体目），两种属于肌尾噬菌体科，其他的归为短尾噬菌体科和长尾噬菌体科。对它们的基因组进行测序，揭示出双链DNA拓扑结构，基因组大小在42 kb到65 kb之间。在分离和鉴定这些新型噬菌体时，我们致力于将这些噬菌体开发并用作噬菌体疗法的候选物，作为管理或消除这些致病菌株的替代策略。在此，我们描述了用于潜在治疗澳大利亚多重耐药临床分离株的新型噬菌体候选物。
